(Q37590854)

21 August 2017

1 reference

title

Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). (English)

1 reference

21 August 2017

1 reference

1 reference

2

Gillian M Keating

1 reference

21 August 2017

Jamie D Croxtall

1

1 reference

21 August 2017

publication date

1 January 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

11

1 reference

21 August 2017

issue

5

1 reference

21 August 2017

page(s)

349-357

1 reference

https://scigraph.springernature.com/pub.10.2165/11202760-000000000-00000

21 August 2017

exact match

0 references

cites work

Thymus-independent and thymus-dependent responses to polysaccharide antigens

2 references

https://api.crossref.org/works/10.2165%2F11202760-000000000-00000

21 January 2018

12 December 2020

Respiratory infections caused by non-typeable Haemophilus influenzae

1 reference

https://api.crossref.org/works/10.2165%2F11202760-000000000-00000

Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202760-000000000-00000

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202760-000000000-00000

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11202760-000000000-00000

Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada

21 January 2018

1 reference

12 December 2020

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

1 reference

12 December 2020

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

1 reference

12 December 2020

Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera

1 reference

12 December 2020

Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines

1 reference

12 December 2020

Nontypeable Haemophilus influenzae: pathogenesis and prevention

1 reference

12 December 2020

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

1 reference

12 December 2020

Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants

1 reference

12 December 2020

Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study

1 reference

12 December 2020

Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells

1 reference

12 December 2020

Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).

1 reference

12 December 2020

Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children

1 reference

12 December 2020

DTaP-IPV/Hib vaccine (Pentacel).

1 reference

12 December 2020

Kinetics of the immune response following pneumococcal PD conjugate vaccination

1 reference

12 December 2020

Bacterial otitis media: a vaccine preventable disease?

1 reference

12 December 2020

ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media

1 reference

12 December 2020

Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines

1 reference

12 December 2020

The prevention of pneumococcal disease in children

1 reference

12 December 2020

Pneumococcal Haemophilus influenzae protein D conjugate vaccine induces antibodies that inhibit glycerophosphodiester phosphodiesterase activity of protein D.

1 reference

12 December 2020

Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics.

1 reference

12 December 2020

The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity

1 reference

12 December 2020

treatment and prevention of otitis media

1 reference

12 December 2020

10.2165/11202760-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

21 August 2017

1009532303

0 references

1 reference